Abstracts tagged "Activity score and psoriatic arthritis"

Abstract Number: 1723 • 2016 ACR/ARHP Annual Meeting
Composite Psoriatic Disease Activity Index (CPDAI), Defining Remission and Disease Activity States Using Data from Daily Clinical Practice
Maria Laura Acosta Felquer¹, Agnes Szentpetery^2,3,4,5, Musaab Elmamoun⁶, Phil Gallagher⁴, Oliver FitzGerald⁷ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁵Bone & Joint Unit, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁶Rheumatology, St. Vincent's University Hospital, Department of Rheumatology, Dublin 4, Ireland, ⁷St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: The Composite Psoriatic Disease Activity Index (CPDAI), a composite disease outcome measure in psoriatic arthritis (PsA) (1),has proved to be a valid and discriminative…
Abstract Number: 1585 • 2014 ACR/ARHP Annual Meeting
Presence of Swollen and Tender Joints in Patients Fulfilling Minimal Disease Activity Criteria
Josefina Marin¹, Maria L. Acosta Felquer², Leandro Ferreyra-Garrot¹, Santiago Ruta³, Javier Rosa¹ and Enrique R. Soriano⁴, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Internal Medicine, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina
Background/Purpose Minimal disease activity (MDA) is a composite measure created for patients with psoriatic arthritis (PsA) that encompasses many clinically important aspects of PsA: arthritis,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].